Piper Jaffray Reiterates an 'Overweight' Rating on Human Genome Sciences (HGSI); Optimistic About BLISS-76 Data in November
Tweet Send to a Friend
Piper Jaffray & Co. reiterates an Overweight on Human Genome Sciences (Nasdaq: HGSI), raises price target from $15 to $25 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
